Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 24, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Langerhans cell histiocytosis.

Ligaya Park1, Clayton Schiltz, Neil Korman

  • 1Department of Dermatology, Case Medical Center, Cleveland, OH, USA. ligaya.park@uhhospitals.org

Journal of Cutaneous Medicine and Surgery
|March 16, 2012
PubMed
Summary

Cutaneous Langerhans cell histiocytosis (LCH) is rare and variable, delaying diagnosis. Skin biopsies confirm LCH, with treatment often starting with steroids, adjusting based on response.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of GLP-1 receptor agonists on clinical outcomes and healthcare utilization in hidradenitis suppurativa patients: A retrospective cohort study using TriNetX.

Journal of the American Academy of Dermatology·2025
Same author

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.

Journal of the American Academy of Dermatology·2018
Same author

T-cell-mediated immune response to pneumococcal conjugate vaccine (PCV-13) and tetanus toxoid vaccine in patients with moderate-to-severe psoriasis during tofacitinib treatment.

Journal of the American Academy of Dermatology·2017
Same author

Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS).

Seminars in arthritis and rheumatism·2015
Same author

Psoriasis as a systemic disease.

Clinics in dermatology·2014
Same author

Staged island pedicle flap and tube flap to repair a full-thickness defect of the upper third of the ear.

Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]·2013

Area of Science:

  • Dermatology
  • Pediatric Pathology
  • Oncology

Background:

  • Cutaneous Langerhans cell histiocytosis (LCH) is an uncommon condition with diverse presentations.
  • Variability in skin manifestations can impede timely diagnosis.

Observation:

  • This study reviews a case of cutaneous LCH and relevant literature.
  • Diagnostic criteria include skin biopsies positive for CD1a and/or langerin.

Findings:

  • Evaluation involves a comprehensive review of systems, laboratory tests, and imaging to assess LCH extent.
  • Initial treatment for cutaneous LCH typically involves topical or oral steroids.
  • Treatment response assessment at six weeks guides therapy intensification for systemic disease.

Implications:

  • Lack of specific LCH treatment guidelines necessitates reliance on Histiocyte Society recommendations.
  • Standardized diagnostic and treatment approaches are crucial for improving patient outcomes in rare LCH cases.

More Related Videos

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: May 24, 2026

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation
07:17

Wild-type Blocking PCR Combined with Sanger Sequencing for Detection of Low-frequency Somatic Mutation

Published on: August 23, 2024

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019